Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fyodor Biotechnologies
Baltimore, Maryland, United Statesfyodorbio.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Commercial
01
Overview
Fyodor Biotechnologies has developed and commercialized the Urine Malaria Test (UMT), the world’s first non-blood rapid diagnostic test for malaria. The UMT uses a urine sample to detect malaria antigens with accuracy comparable to blood-based rapid tests. It has received regulatory approvals in several African countries and CE Mark certification[3][6][8].
- Therapeutic areas
- Infectious Diseases
- Modalities
- DeviceRecombinant monoclonal antibody
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
Johns Hopkins UniversityDuke UniversityUniversity of LagosTEDCOMaryland Industrial Partnerships Program
Beyond the preview
Go deeper on Fyodor Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fyodor Biotechnologies.